Enveric Biosciences (NASDAQ: ENVB) has reported new preclinical findings for EB-003, an experimental drug being developed to deliver potential neurological benefits associated with psychedelics without producing hallucinogenic effects. Announced on 4 November 2026, the findings come from a quantitative electroencephalography (qEEG) study in mice, which examined how EB-003 influences electrical activity in the brain.

